Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 45   

Articles published

ALKS 43.21 -3.11 (-6.71%)
price chart
Alkermes plc Reports Second Quarter 2014 Financial Results
DUBLIN, Jul 31, 2014 (BUSINESS WIRE) -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the second quarter of 2014.
Alkermes softens guidance after Q2 results (ALKS)  Seeking Alpha (registration)
Related articles »  
Is Alkermes plc Stock Undervalued?
In simple terms, what Alkermes plc (NASDAQ: ALKS ) is attempting to do is not easy. Few companies manage to successfully transition from being a licensor of drug formulation technologies to a proprietary drug developer and likewise few independent ...
Alkermes Plc (ALKS) to Release Earnings on Thursday
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) will post its Q314 quarterly earnings results on Thursday, July 31st. Analysts expect Alkermes Plc to post earnings of $0.14 per share and revenue of $146.91 million for the quarter. Individual that are ...
Alkermes plc (ALKS) Receives Notice of Allowance from USPTO Covering Four ...
Alkermes plc (Nasdaq: ALKS) announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four of Alkermes' pipeline candidates for the treatment of central nervous system (CNS) disorders: aripiprazole ...
Insider Selling: Michael J. Landine Unloads 7000 Shares of Alkermes Plc ...  Intercooler
Alkermes Announces Notices of Allowance for US Patents for Four CNS Pipeline ...  MarketWatch
Related articles »  
Alkermes plc: Alkermes to Host Conference Call to Discuss Second Quarter ...
24, 2014-- Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, July 31, 2014, to discuss the company's financial results for the second quarter of 2014.
Related articles »  
Insider Selling: Alkermes Plc CEO Sells 50000 Shares of Stock (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) CEO Richard F. Pops sold 50,000 shares of Alkermes Plc stock in a transaction dated Wednesday, July 2nd.
Insider Selling: Richard F. Pops Unloads 50000 Shares of Alkermes Plc Stock ...  Mideast Time
Drug Delivery: Valeant Pharmaceuticals International (NYSE:VRX), Alkermes ...  Gaining Green
Related articles »  
Alkermes Plc's Neutral Rating Reaffirmed at Zacks (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS)'s stock had its �neutral� rating reiterated by Zacks in a report released on Friday.
Alkermes Plc Receives Consensus Rating of �Buy� from Analysts (NASDAQ:ALKS)  Intercooler
Insider Selling: James M. Frates Sells 7000 Shares of Alkermes Plc Stock (ALKS)  Watch List News (press release)
Related articles »  
Alkermes Plc COO Sells $743840 in Stock (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) COO Gordon G. Pugh unloaded 16,000 shares of the stock in a transaction dated Tuesday, July 1st.
Alkermes Plc Given Neutral Rating at Zacks (ALKS)
Zacks reaffirmed their neutral rating on shares of Alkermes Plc (NASDAQ:ALKS) in a report issued on Friday. They currently have a $50.00 target price on the stock.
Drug Delivery: Valeant Pharmaceuticals Intl Inc. (NYSE:VRX), Alkermes Plc ...  Crazy Joys
Related articles »  
Alkermes Plc Given Average Recommendation of �Buy� by Brokerages ...
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) has received a consensus recommendation of �Buy� from the nine analysts that are covering the company, Analyst Ratings.
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for ...  Wall Street Journal
Related articles »